Recent Pfizer Press Releases

8/26/15 7:30am EDT
Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor–Positive Early Breast Cancer

Partnership with Pfizer, BIG, GBG, NSABP and PrECOG to facilitate further investigation of IBRANCE

The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. today announced the launch of the Palbociclib Collaborative AdjuvantStudy, or PALLAS.

8/24/15 8:15am EDT
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015

  • Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating the risk of major bleeding, bleeding-related hospital readmissions, hospitalization rates and healthcare costs among patients with nonvalulvar atrial fibrillation (NVAF) receiving novel oral anticoagulant (NOACs)
  • Results from the AEGEAN (Assessment of an Educational and Guidance Programme for Eliquis Adherence in Nonvalvular Atrial Fibrillation) study will also be presented as a late-breaking trial

8/24/15 8:00am EDT
Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition

  • FTC Consent Order includes agreement to divest four sterile injectable assets
  • Brazil’s Superintendency-General of the Council for Economic Defense (CADE) has published its unconditional clearance decision
  • Transaction expected to close in early September 2015

Pfizer Inc. today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Hospira. 

8/21/15 8:00am EDT
Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA® (Meningococcal Group B Vaccine)

Data Consistent with Immunogenicity and Safety Data from Previous Studies

Pfizer Inc. (NYSE:PFE) announced today positive topline results of two Phase 3 studies of TRUMENBA® (Meningococcal Group B Vaccine). 

8/20/15 11:23am EDT
Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer

Pfizer Inc. today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for IBRANCE® (palbociclib) in combination with endocrine therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.

8/14/15 8:35am EDT
Pfizer Granted Approval From The Canadian Competition Bureau For Hospira Acquisition

Approval Includes Certain Commitments

Pfizer Inc. (NYSE: PFE) today announced that it was granted approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira (NYSE: HSP). As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada.

8/13/15 8:15am EDT
Pfizer Receives Approval from the Australian Competition and Consumer Commission for Pending Acquisition of Hospira

Pfizer Inc. (NYSE:PFE) today announced that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Hospira, Inc. (NYSE:HSP) and found no need for remedies.

8/4/15 11:36am EDT
Pfizer Receives Approval From European Commission For Pending Acquisition Of Hospira

European Commission Approval Includes Certain Commitments

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company’s pending acquisition of Hospira, Inc. (NYSE: HSP).

8/3/15 8:30am EDT
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

Synthon’s glatiramer acetate, a potential generic version of Copaxone®1 for the treatment of relapsing remitting multiple sclerosis is currently being reviewed by the U.S. Food and Drug Administration

Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).

7/28/15 7:00am EDT

Pfizer Inc. (NYSE: PFE) reported financial results for secondquarter 2015 and announced increases to the midpoints of its 2015 financial guidance(3) ranges for reported revenues(1) and reported(1) and adjusted(2) diluted EPS.
7/22/15 8:30am EDT
Pfizer Announces Expansion of Lease Agreement with Massachusetts Institute of Technology Subsidiary for Kendall Square Research Facility

Consolidation of Cambridge Research Centers Creates a Single Pfizer Cambridge Campus to Help Expedite Discovery and Development Efforts and Encourage Creative Collaboration

Pfizer announced today the expansion of its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus in Kendall Square (KSQ).

7/8/15 8:30am EDT
Pfizer’s Centers For Therapeutic Innovation And Jeffrey Modell Foundation Announce Collaboration to Help Advance Immunological Research

New Collaboration Aligns with Pfizer’s Commitment to Immunology and Rare Disease Drug Discovery

Pfizer’s Centers for Therapeutic Innovation (CTI) and the Jeffrey Modell Foundation (JMF) announced today a collaboration agreement to conduct research in the field of immunological diseases. 

7/7/15 8:00am EDT
Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery

Pfizer Inc. (NYSE: PFE) announced today enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery.

7/2/15 4:30pm EDT
Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate) Modified Release Tablets

Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) accepted for review Pfizer’s new drug application (NDA) for XELJANZ® (tofacitinib citrate) 11 mg once daily modified release tablets for the treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX).

6/25/15 11:20am EDT
Joseph J. Echevarria Elected To Pfizer’s Board Of Directors

Pfizer Inc. today announced the election of Joseph J. Echevarria to its Board of Directors, effective immediately. Mr. Echevarria also was appointed to the Audit, Regulatory and Compliance and Science and Technology Committees of Pfizer’s Board.

6/25/15 11:15am EDT
Pfizer Declares 28-Cent Third-Quarter 2015 Dividend

The board of directors of Pfizer Inc. today declared a 28-cent third-quarter 2015 dividend on the company’s common stock, payable September 2, 2015, to shareholders of record at the close of business on August 7, 2015. 

6/24/15 1:19pm EDT
CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA® for Adolescents and Young Adults 16 through 23 Years of Age

Committee’s Recommendation Allows for Individual Clinical Decision

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with healthcare providers. 

6/23/15 2:00pm EDT
Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease

RESET Trial to Assess Effectiveness and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Individuals with Sickle Cell Disease

Pfizer Inc. (NYSE:PFE) today announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study – a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are six years of age or older.

6/23/15 10:00am EDT
Pfizer Invites Public To View And Listen To Webcast Of July 28 Conference Call With Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 28, 2015. 

6/23/15 8:00am EDT
New Online Community, Quitter’s Circle, Helps Smokers Trade Cigarettes for Real-Time Support

The American Lung Association and Pfizer (NYSE:PFE) today announced the launch of Quitter’s Circle, a mobile app and online community designed to help smokers face common obstacles associated with quitting through educational, social and financial support.